Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis (Nature Medicine, (2021), 27, 5, (802-805), 10.1038/s41591-021-01324-7)

Toni K. Choueiri, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. McDermott, M. Dror Michaelson, Leonard J. Appleman, Sanjay Thamake, Rodolfo F. Perini, Naseem J. Zojwalla, Eric Jonasch

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the version of this Letter initially published, the Acknowledgements section omitted the following text: “T.K.C. is supported in part by the Dana–Farber/Harvard Cancer Center Kidney Specialized Program of Research Excellence and program, the Kohlberg Chair at Harvard Medical School, the Trust Family, Michael Brigham, and Loker Pinard Funds for Kidney Cancer Research at Dana–Farber Cancer Institute, and by various grants from the National Cancer Institute, Department of Defense, and foundations. Authors were also supported by NCI grants P50 CA101942 and U01 CA236489 to D.F.M. and T.K.C.” This addition has now been included in the Acknowledgements. The original Letter has been corrected in the online version of the paper.

Original languageEnglish (US)
Pages (from-to)1849
Number of pages1
JournalNature medicine
Volume27
Issue number10
DOIs
StatePublished - Oct 2021
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis (Nature Medicine, (2021), 27, 5, (802-805), 10.1038/s41591-021-01324-7)'. Together they form a unique fingerprint.

Cite this